

THE SCIENCE OF STAYING HEALTHY

Beyond health clinics, longevity as an industry is hard to define.

Venture capital data firm PitchBook uses the phrase “longevity tech” to describe companies researching and developing restorative and antiaging treatments that ultimately aim to increase lifespan. In contrast to companies that develop therapies to treat age-related diseases like diabetes and heart disease, longevity companies focus on extending lives by preventing diseases before they manifest.

With backing by tech billionaires like Jeff Bezos and Sam Altman, “momentum is building as longevity biotech shifts from speculative science to a potential cornerstone of future health care,” PitchBook said in an April 2025 brief.

But these are early days. Just last month, Boston startup Life Biosciences became the first company ever to gain U.S. Food and Drug Administration approval for an early-stage clinical trial of a gene therapy to reverse vision loss in people with glaucoma. In January, San Francisco-based Loyal got a safety acceptance from the FDA, moving it one step closer to approval for its drug candidate to extend the healthy lifespan of dogs.

The advances helped land them on PitchBook’s top 10 list of VC-backed longevity tech companies. No Seattle-area startups made the list, but there are a handful of venture- or investor-backed companies in the region, most in pre- or early-seed stages.


— *Cathy Duchamp*



Bezos

Altman

PUGET SOUND REGION’S NACENT LONGEVITY HEALTH INDUSTRY



FUNDING INFUSIONS

Top 10 raises by longevity technology companies in the U.S. from 2021 to present:

\$3B
Altos Labs • Deal closed Jan. 2022 •
Lead/notable investors: ARCH Venture Partners

\$1B
Retro • Jan. 2025 • Sam Altman

\$270M
Altos Labs • Sept. 2021 • Jeff Bezos

\$180M
Retro • April 2022 • Sam Altman

\$100M
Loyal • Feb. 2026 • Age 1

\$82M
Life Biosciences • Sept. 2021
Alpha Wave Global

\$76M
Loyal • March 2024 • Bain Capital Ventures

\$50M
Gordian Biotechnology • Dec. 2021
Laura Deming

\$40M
Rubedo • July 2024 • Ahren Innovation
Capital; Khosla Ventures

\$40M
Elevian • Sept. 2021 • Prime Movers Lab

Oisín Biotechnologies

HQ: Seattle • CEO: Matthew Scholz
Employees: 17

Objective: Develops genetic medicines to address aging, age-related disease

Ora Biomedical

HQ: Tukwila • CEO: Ben Blue •
Employees: 8

Objective: Uses artificial intelligence, robotics and live-animal screening to identify therapies that help with aging

Phenome Health

HQ: Seattle • CEO: Dr. Lee Hood
Employees: 15

Objective: Nonprofit that uses advanced analytics and AI to predict and prevent diseases with the goal of increasing individual healthspan

SOURCE: PITCHBOOK,
INDIVIDUAL COMPANIES

Optispan

HQ: Tukwila • CEO: Matt Kaerberlein
Employees: 12

Objective: Concierge medicine company that uses biomarker testing, AI-enhanced diagnostics to develop personalized preventive treatments to increase individual health spans

Circulate Health

HQ: Seattle • Dr. Brad Younggren
Employees: 45

Objective: Therapeutic plasma exchange that separates, removes and replaces a patient’s plasma to treat inflammation, improve healthspan and address certain chronic diseases

Viome Life Sciences

HQ: Bellevue • CEO: Naveen Jain
Employees: 160

Objective: Makes sells at-home gut health, oral health and full-body health tests to identify issues; sells tailored supplements to improve health